Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells
Name
11095_2023_Article_3471.pdf
Size
1005.16 KB
Format
Adobe PDF
Checksum (MD5)
325dbfa262b1a0ef9b3c8fb5fafaee8c
Author(s)
Liu, Gary W.
Guzman, Edward B.
Menon, Nandita
Langer, Robert S.
Date Issued
February 3, 2023
Publisher
Springer US
Citation
Liu, Gary W., Guzman, Edward B., Menon, Nandita and Langer, Robert S. 2023. "Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells."
Version
Final published version
Abstract
Abstract
Endothelial cells play critical roles in circulatory homeostasis and are also the gateway to the major organs of the body. Dysfunction, injury, and gene expression profiles of these cells can cause, or are caused by, prevalent chronic diseases such as diabetes, cardiovascular disease, and cancer. Modulation of gene expression within endothelial cells could therefore be therapeutically strategic in treating longstanding disease challenges. Lipid nanoparticles (LNP) have emerged as potent, scalable, and tunable carrier systems for delivering nucleic acids, making them attractive vehicles for gene delivery to endothelial cells. Here, we discuss the functions of endothelial cells and highlight some receptors that are upregulated during health and disease. Examples and applications of DNA, mRNA, circRNA, saRNA, siRNA, shRNA, miRNA, and ASO delivery to endothelial cells and their targets are reviewed, as well as LNP composition and morphology, formulation strategies, target proteins, and biomechanical factors that modulate endothelial cell targeting. Finally, we discuss FDA-approved LNPs as well as LNPs that have been tested in clinical trials and their challenges, and provide some perspectives as to how to surmount those challenges.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s11095-023-03471-7
